CTX

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
1 program
1
Blinded CDCA 250 mg TIDPhase 31 trial
Active Trials
NCT04270682Completed19Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mirum PharmaceuticalsBlinded CDCA 250 mg TID

Clinical Trials (1)

Total enrollment: 19 patients across 1 trials

NCT04270682Mirum PharmaceuticalsBlinded CDCA 250 mg TID

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Start: Jan 2020Est. completion: Oct 202319 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space